API Anti Virus Hepatitis B Treatment Epivir CAS 134678-17-4

Pharmaceutical API Anti Virus Hepatitis B Treatment Epivir CAS 134678-17-4 Lamivudine

Product Introduction

Name: Lamivudine
English synonym: Epivir
CAS number: 134678-17-4
Molecular formula: C8H11N3O3S
Molecular weight: 229.26
EINECS Number: 603-844-3

Product Description

Melting point: 177°C
Specific rotation: D21-135°(c=0.38 in methanol)
Boiling point: 475.4±55.0°C (Predicted)
Density: 1.73±0.1g/cm3(Predicted)
Refractive index: -142°(C=1, MeOH)
Flash point: 9℃
Storage conditions: 2-8°C
Solubility: water:soluble10mg/mL, clear
Acidity coefficient (pKa): 13.83±0.10 (Predicted)
Form: powder
Color: white to beige
Water solubility: 70g/L (temperature not stated)

Product Function

Lamivudine can be metabolized in HBV-infected cells and normal cells to generate lamivudine triphosphate, which is the active form of lamivudine and is both an inhibitor of HBV polymerase and a substrate for this polymerase. Lamivudine triphosphate is incorporated into the viral DNA chain, blocking the synthesis of viral DNA, and does not interfere with the metabolism of deoxynucleoside in normal cells, has weak inhibitory effects on mammalian DNA polymerase α and β, and has a weak inhibitory effect on mammalian DNA polymerases. Cellular DNA content had little effect. No obvious toxicity to mitochondrial structure, DNA content and function.

The serum HBV-DNA detection results of most hepatitis B patients showed that lamivudine could rapidly inhibit HBV replication, and its inhibitory effect continued throughout the course of treatment. At the same time, serum transaminases are reduced to normal, and long-term application can significantly improve liver necro-inflammatory changes and reduce or prevent the progress of liver fibrosis.